chemotherapy-induced antitumor immunity requires formyl peptide receptor 
antitumor immunity driven intratumoral dendritic cells contributes efficacy anthracycline-based chemotherapy cancer identified loss-of-function allele gene coding formyl peptide receptor fpr1 associated poor metastasis-free overall survival breast colorectal cancer patients receiving adjuvant chemotherapy therapeutic effects anthracyclines abrogated tumor-bearing fpr1-/- mice due impaired antitumor immunity fpr1-deficient dendritic cells failed approach dying cancer cells result elicit antitumor t cell immunity experiments performed microfluidic device confirmed fpr1 ligand annexin- promoted stable interactions dying cancer cells human murine leukocytes altogether results highlight importance fpr1 chemotherapy-induced anticancer immune responses 
